Increased expression of mRNA for myocyte-specific enhancer binding factor (MEF) 2C in the cerebral cortex of the itching mouse

Neuroscience Research
C TohdaY Kuraishi

Abstract

Since itch can be a subjective sensation, markedly affected by psychological conditions or sometimes originate in the central nervous system, the mechanisms of neuronal processing of itch signaling in the central nervous system should be studied. Therefore, we examined itch-related behaviors and nervous gene expressions of NC mice, which show severe dermatitis and atopy-like changes in inflammatory cells. Some NC mice spontaneously scratched their bodies and showed skin lesions, such as eczema, bleeding and alopecia from 2-6 months after birth. The mice with skin lesions scratched mainly the face, ears and rostral part of the body throughout the day, using their hind paws . The average scratching frequency was 126.7 +/- 36.8 (n = 4) and 5.3 +/- 4.7 (n = 3) per h in skin-lesioned and non-lesioned control mice, respectively. A differential display analysis of gene expressions in several regions in central and peripheral nervous systems was performed between these scratching and control groups. One of the genes that was expressed at a higher level in a scratching group than in the control group was myocyte-specific enhancer binding factor (MEF) 2C, in the cerebral cortex. The scratching was inhibited by intracerebroventricular inj...Continue Reading

References

May 1, 1990·Hepatology : Official Journal of the American Association for the Study of Liver Diseases·E A Jones, N V Bergasa
May 1, 1988·Pain·J C BallantyneD B Carr
Mar 14, 1995·European Journal of Pharmacology·Y KuraishiM Satoh
Feb 15, 1993·Proceedings of the National Academy of Sciences of the United States of America·D LeiferS A Lipton
Apr 1, 1993·Molecular and Cellular Biology·J C McDermottB Nadal-Ginard
Jun 1, 1993·Proceedings of the National Academy of Sciences of the United States of America·J F MartinE N Olson

❮ Previous
Next ❯

Citations

May 18, 2000·Phytotherapy Research : PTR·C TohdaK Komatsu
Jan 13, 2001·Journal of Dermatological Science·T YamaguchiY Kuraishi
May 9, 2003·Biological & Pharmaceutical Bulletin·Tomomi Yamaguchi-MiyamotoHideyo Suzuki
Apr 13, 2002·Japanese Journal of Pharmacology·Takayuki MiyamotoYasushi Kuraishi
Nov 7, 2002·Japanese Journal of Pharmacology·Tatsuya MaekawaYasushi Kuraishi
Dec 16, 2011·The Journal of Investigative Dermatology·Nari KimZae Young Ryoo
Feb 17, 2006·Experimental Dermatology·A TakaokaS Nakaike
Nov 24, 2004·European Journal of Pharmacology·Iwao AraiShiro Nakaike
Oct 20, 2005·Experimental Dermatology·N TakahashiS Nakaike
May 12, 2005·Experimental Dermatology·Masanori FujiiShigekatsu Kohno
Jul 18, 2006·Experimental Dermatology·Masanori SugimotoShiro Nakaike
Jan 13, 2015·Immunopharmacology and Immunotoxicology·Tasuku NakasoneChiaki Kamei
Nov 9, 2005·Journal of Pharmacological Sciences·Norikazu TakanoMichio Kurachi
Dec 20, 2005·European Journal of Pharmacology·Masanori FujiiShigekatsu Kohno
Feb 28, 2002·The European Journal of Neuroscience·Tomás L FalzoneMarcelo Rubinstein

❮ Previous
Next ❯

Related Concepts

Related Feeds

Antisense Oligonucleotides: ND

This feed focuses on antisense oligonucleotide therapies such as Inotersen, Nusinursen, and Patisiran, in neurodegenerative diseases including amyotrophic lateral sclerosis.